Physician profile

Marvin Chadab

Dermatology · Oxon Hill, MD

NPI 1376724583

$2,900.16

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $888.30 2019-2020
Encore Dermatology INC. $309.64 2019-2020
Pfizer INC. $276.52 2019-2020
Janssen Biotech, INC. $191.44 2019-2020
Journey Medical Corporation $163.59 2019
Lilly USA, LLC $156.74 2019-2020
Celgene Corporation $122.27 2019
Novartis Pharmaceuticals Corporation $117.89 2019
Mayne Pharma Commercial LLC $116.76 2019
Galderma Laboratories, L.P. $113.56 2019
Janssen Scientific Affairs, LLC $103.92 2019
Ortho Dermatologics, A Division of Bausch Health US, LLC $73.58 2019-2020
Sun Pharmaceutical Industries INC. $39.32 2019
Regeneron Healthcare Solutions, INC. $37.18 2019
Vyne Pharmaceuticals INC. $36.27 2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Leo Pharma INC. $26.24 2019
Sebela Pharmaceuticals INC. $20.86 2019
Promius Pharma LLC $20.50 2019
Dermira, INC. $17.18 2019
Mission Pharmacal Company $15.43 2019
Almirall LLC $13.77 2019
Genzyme Corporation $13.46 2019
Medimetriks Pharmaceuticals, INC. $13.17 2019
Merck Sharp & Dohme LLC $12.57 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marvin Chadab

$2,900.16

in general payments reported 2019-2025

Years
2019-2020
Top company
Abbvie INC.

https://glasscript.com/doctor/335082/marvin-chadab

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.